| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Vestronidase alfa |
| Brand | MEPSEVII® |
| Indication | For the treatment of non-neurological manifestations of MPS VII. |
| Assessment Process | |
| Rapid review commissioned | 09/04/2019 |
| Rapid review completed | 22/05/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.